20 articles
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
New research shows phosphatidylserine supplementation reduces liver fat and inflammation while improving glucose control through enhanced fat metabolism.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
New research reveals semaglutide's liver benefits work independently of weight loss through specialized liver blood vessel cells.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Novel obesity drug targeting two pathways simultaneously shows unprecedented weight loss results in recent clinical studies.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.
VA study tests whether combining lifestyle changes with metformin can reverse muscle loss and frailty in obese older adults.
50 nm polystyrene nanoplastics accumulate in mouse testes, degrading sperm quality and triggering iron-dependent cell death through a newly identified mitochondrial pathway.
Inclisiran safely reduced LDL cholesterol by 28% in adolescents with familial hypercholesterolemia, offering hope for early intervention.
Scientists discover vitamin B3 can target a key genetic driver of fatty liver disease, offering hope for 30% of people affected globally.
Experimental diabetes drug IC7Fc reduces cholesterol and artery plaque buildup, offering cardiovascular benefits even without weight loss.
Combining cold exposure with exercise activates a key metabolic pathway to reduce liver fat and fibrosis more effectively than either intervention alone.
